Recombinant virus-like particles as a carrier of B- and T-cell epitopes of hepatitis C virus (HCV)

Vaccine

Volumn 24, Issue 20, 2006, Pages 4369-4377

  Mihailova, Marija ^a,b   Boos, Mechthild ^a   Petrovskis, Ivars ^b   Ose, Velta ^b   Skrastina, Dace ^b   Fiedler, Melanie ^a   Sominskaya, Irina ^b   Ross, Stefan ^a   Pumpens, Paul ^b   Roggendorf, Michael ^a   Viazov, Sergei ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF LATVIA   (Latvia)

Author keywords

Hepatitis C virus; Vaccine; Virus like particles

Indexed keywords

CHIMERIC PROTEIN; EPITOPE; HEPATITIS B CORE ANTIGEN; HEPATITIS C ANTIGEN; HEPATITIS C VACCINE; NONSTRUCTURAL PROTEIN 3; PROTEIN ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; GEL FILTRATION; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECOMBINANT PLASMID; SUCROSE DENSITY GRADIENT CENTRIFUGATION; T LYMPHOCYTE; VIRUS GENE; VIRUS PARTICLE; VIRUS RECOMBINANT;

ANIMALS; B-LYMPHOCYTES; CELL PROLIFERATION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; EPITOPES; FEMALE; HEPACIVIRUS; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES; VIRION;

EID: 33646128931     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.02.051     Document Type: Article

References (30)

1. Neumann-Haefelin C., Blum H.E., Chisari F.V., and Thimme R. T cell response in hepatitis C virus infection. J Clin Virol 32 2 (2005) 75-85
2. Rollier C., Depla E., Drexhage J.A., Verschoor E.J., Verstrepen B.E., Fatmi A., et al. Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine induced peripheral T-helper immune response. J Virol 78 1 (2004) 187-196
3. Bowen D.G., and Walker C.M. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436 7053 (2005) 946-952
4. Torresi J., Bharadwaj M., Lackson D.C., and Gowans E.J. Neutralising antibody, CTL and dendritic cell responses to hepatitis C virus: a preventive vaccine strategy. Curr Drug Targets 5 1 (2004) 41-56
5. Rehermann B., and Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 5 3 (2005) 215-229
6. Houghton M., and Abrignanl S. Prospects for a vaccine against the hepatitis C virus. Nature 436 7053 (2005) 961-966
7. Lechner F., Jegerlehner A., Tissot A.C., Maurer P., Sebbel P., Renner W.A., et al. Virus-like particles as a modular system for novel vaccines. Intervirology 45 4-6 (2002) 212-217
8. Inchauspe G., and Feinstone S. Development of a hepatitis C virus vaccine. Clin Liver Dis 7 1 (2003) 243-259
9. Encke J., Findeklee J., Geib J., Pfaff E., and Stremmel W. Prophylactic and therapeutic vaccination with dendritic cells against hepatitis C virus infection. Clin Exp Immunol 142 2 (2005) 362-369
10. Duenas-Carrera S. DNA vaccination against hepatitis C. Curr Opin Mol Ther 6 2 (2004) 146-150
11. Ulrich R., Nassal M., Meisel H., and Kruger D.H. Core particles of hepatitis B virus as carrier for foreign epitopes. Adv Virus Res 50 (1998) 141-182
12. Pumpens P., and Grens E. HBV core particles as a carrier for B cell/T cell epitopes. Intervirology 44 2-3 (2001) 98-114
13. Oliveira G.A., Wetzel K., Calvo-Calle J.M., Nussenzweig R., Schmidt A., Birkett A., et al. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial. Infect Immun 73 6 (2005) 3587-3597
14. Nassal M. Total chemical synthesis of a gene for hepatitis B virus core protein and its functional characterization. Gene 66 2 (1988) 279-294
15. Birnbaum F., and Nassal M. Hepatitis B virus nucleocapsid assembly: primary structure requirements in the core protein. J Virol 64 7 (1990) 3319-3330
16. Borisova G.P., Kalis I.V., Pushko P.M., Tsibinogin V.V., and Loseva V. Genetically engineered mutants of the core antigen of the human hepatitis B virus preserving the ability for native self-assembly. Dokl Akad Nauk SSSR 298 6 (1988) 1474-1478 (in Russian)
17. Lohmann V., Hoffmann S., Herian U., Penin F., and Bartenschlager R. Viral and cellular determinants of hepatitis C virus RNA replication in cell culture. J Virol 77 5 (2003) 3007-3019
18. Riedl P., Stober D., Oehninger C., Melber K., Reimann J., and Schirmbeck R. Priming Th1 immunity to viral core particles is facilitated by trace amounts of RNA bound to its arginine-reach domain. J Immunol 168 10 (2002) 4951-4959
19. Storni T., Ruedl C., Schwarz K., Schwendener R.A., Renner W.A., and Bachmann M.F. Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol 172 3 (2004) 1777-1785
20. Mason P.W., Rieder E., and Baxt B. RGD sequence of foot-and-mouth disease virus is essential for infecting cells via the natural receptor but can be bypassed by an antibody-dependent enhancement pathway. Proc Natl Acad Sci USA 91 5 (1994) 1932-1936
21. Konig S., Beterams G., and Nassal M. Mapping of homologous interaction sites in the hepatitis B virus core protein. J Virol 72 6 (1998) 4997-5005
22. Borisova G., Borschukova O., Skrastina D., Dislers A., Ose V., Pumpens P., et al. Behavior of a short preS1 epitope on the surface of hepatitis B core particles. Biol Chem 380 3 (1999) 315-324
23. Gelderblom H., Bauer H., Frank H., and Wigand R. The structure of group II adenoviruses. J Gen Virol 1 4 (1967) 553-560
24. Towbin H., Staehelin T., and Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications, 1979. Biotechnology 24 (1992) 145-149
25. Yoshikawa A., Tanaka T., Hoshi Y., Kato N., Tachibana K., Iizuka H., et al. Chimeric hepatitis B virus core particles with parts or copies of the hepatitis C virus core protein. J Virol 67 10 (1993) 6064-6070
26. Claeys H., Volckaerts A., Mertens W., Liang Z., Fiten P., and Opdenakker G. Localization and reactivity of an immunodominant domain in the NS3 region of hepatitis C virus. J Med Virol 45 3 (1995) 273-281
27. Wu C.L., Leu T.S., Chang T.T., and Shiau A.L. Hepatitis C virus core protein fused to hepatitis B virus core antigen for serological diagnosis of both hepatitis C and hepatitis B infections by ELISA. J Med Virol 57 2 (1999) 104-110
28. Pumpens P., and Grens E. Artificial genes for chimeric virus-like particles. In: Khudyakov Y.E., and Fields H.A. (Eds). Artificial DNA: methods and applications (2002), CRC Press LLC, Boca Raton 249-327
29. Okada N., Tsukada Y., Nakagawa S., Mizuguchi H., Mori K., Saito T., et al. Efficient gene delivery into dendritic cells by fiber-mutant adenovirus vectors. Biochem Biophys Res Commun 282 1 (2001) 173-179
30. Schodel F., Moriarty A.M., Peterson D.L., Zheng J.A., Hughes J.L., Will H., et al. The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity. J Virol 66 1 (1992) 106-114